Delivery Order SPE2DB24D1104-SPE2DB25FYDV7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $74,612.17. This non-competitive delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $7,613.10 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (quantity: 30 count) under a firm fixed price contract. This non-competitive delivery order was issued on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is an atypical antipsychotic medication used to treat schizophrenia and...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) with a ceiling value of $18,361.12. This firm fixed-price, non-set-aside delivery order was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti is an antipsychotic medication used in the...
- The Defense Logistics Agency awarded a delivery order valued at $15,422.40 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 0.5 mg on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract requires delivery to AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $23,642.73 to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is a prescription antipsychotic medication used in treating major...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count packages) valued at $14,929.95 with a firm fixed price structure. This delivery order represents a competitive award with no set-aside designation and is set to conclude by August 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work from its Corporate Office...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYDV7Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,281.82 on July 29, 2025, for the supply of Rexulti 2 mg tablets in quantities of 30. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti is an atypical antipsychotic medication used in the treatment of schizophrenia and major depressive disorder, indicating this delivery supports the military healthcare supply chain's pharmaceutical needs. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. AmerisourceBergen operates as a prime pharmaceutical distributor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical supplies to support military and veteran healthcare systems globally. The company's federal contract portfolio demonstrates consistent success in competitive procurement across multiple therapeutic domains, positioning it as a critical vendor within the Defense Health Agency's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.3k | 7/29/25 |